Document is current
Any future updates will be listed below
-
Authors
Drabe, Camilla Heldbjerg https://orcid.org/0000-0002-9053-9047
Gehrig, Jonathan https://orcid.org/0009-0000-9749-2598
Jensen, Jens Magnus Bernth https://orcid.org/0000-0002-5004-7822
Laustsen, Mira Marie https://orcid.org/0009-0007-3223-0440
Larsen, Carsten Schade https://orcid.org/0000-0002-3963-3804
Sørensen, Camilla Darum https://orcid.org/0000-0002-7170-2734
Dyrmose, Kirstine Overgaard https://orcid.org/0000-0003-3185-9611
Hammer-Hansen, Sophia https://orcid.org/0000-0003-1298-7490
Wittner, Jens https://orcid.org/0000-0002-9729-9111
Masmas, Tania https://orcid.org/0000-0003-1604-422X
Marquart, Hanne https://orcid.org/0000-0001-9740-6522
Ehl, Stephan https://orcid.org/0000-0002-9265-2721
Borgwardt, Line https://orcid.org/0000-0003-1719-9856
Katzenstein, Terese L. https://orcid.org/0000-0002-2233-500X
-
Funding
Funding for this research was provided by:
National Hospital
- License Information
-
More Information
Article History
Received: 3 October 2025
Accepted: 24 May 2026
First Online: 8 June 2026
Declarations
:
: Informed consent to participate in the study and for publication was obtained from all adult study participants and with parental permission provided for minors.
: CD: travel grant and speaker fee: Takeda Pharma. LGB: consultant and speakers fee from Chiesi Farmaceutici S.p.A. TLK: personal fees and grants, including travel grants, from ViiV/Glaxo Smith Kline, Gilead, Merck Sharp & Dohme, CLS Behring, Takeda, Chiesi and Vertex. CSL: Consultant and speakers fee from AstraZeneca, Bavarian Nordic, CSL-Behring, GSK, Moderna, MSD, Pfizer, Takeda and Valneva.All unrelated to the current study.
